ArticleJournal of laboratory physicians
Detection of carbapenemase-producing
Article in Journal of laboratory physicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Carbapenem resistance and associated resistance genes in enterobacteriaceae and non-enterobacteriaceae in India: A systematic review and meta-analysis.The Indian journal of medical research · 2026Pooled it
- Global prevalence and antibiotic resistance profiles of carbapenem-resistantFrontiers in microbiology · 2025Pooled it
- Detection of carbapenem resistance mechanisms in difficult-to-treat Pseudomonas aeruginosa clinical isolates from a tertiary care hospital in Egypt.BMC microbiology · 2026Article
- The emergence of pan-drug-resistantNew microbes and new infections · 2026Article
- Review
- Epidemiological and molecular characterisation of carbapenemase-producing Pseudomonas aeruginosa from a tertiary care hospital, India.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Metallo Beta Lactamase Enzymes.Indian journal of microbiology · 2025Review
- High incidence of carbapenemase-producingJAC-antimicrobial resistance · 2023Article
- Whole-Genome Sequencing Reveals Diversity of Carbapenem-ResistantAntimicrobial agents and chemotherapy · 2022Article
- Carbapenem Combinations for Infections Caused by Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- Demonstration of the efficacy of curcumin on carbapenem-resistant Pseudomonas aeruginosa with Galleria mellonella larvae model.Archives of microbiology · 2022Article
- Diagnosis of Multidrug-Resistant Pathogens of Pneumonia.Diagnostics (Basel, Switzerland) · 2021Review
- Correlation between the Antibiotic Resistance Genes and Susceptibility to Antibiotics among the Carbapenem-Resistant Gram-Negative Pathogens.Antibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbapenemase-producing
aimThe aim of the study was to determine the frequency of carbapenem resistance in clinical isolates of MATERIAL AND
methodsDouble-disk synergy test [DDST] and combined disk synergy test [CDST]) was performed in CRPA isolates and the prevalence of
resultsOf 559 isolates included in the study, a total of 102 isolates were resistant to carbapenem that accounted for overall 18.24% (102/559) prevalence. Of these 102 isolates, 89 (87.25%) isolates were positive by DDST and 95 (93.17%) isolates were positive by CDST. Of 102 CRPA isolates,
conclusionA high rate of carbapenemase production was observed in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.